All In Biotech

NDA 017447 · Pfizer

Norpace

Disopyramide Phosphate · Oral

NovelPriority review

Last checked: Nov 19, 2026Latest source record: May 17, 2000 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1977

Sep 1, 1977

Approved uses

3

Original approval plus efficacy supplements

Registered trials

5

2 Phase 3, 1 recruiting

FAERS reports

853

470 serious, 40 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

Mortality In the National Heart, Lung and Blood Institute's Cardiac Arrhythmia Suppression Trial (CAST), a long-term, multi-center, randomized, double-blind study in patients with asymptomatic non-life-threatening ventricular arrhythmias who had had a myocardial infarction more than 6 days but less than 2 years previously, an excessive mortality or non-fatal cardiac arrest rate (7.7%) was seen in patients treated with encainide or flecainide compared with that seen in patients assigned to carefully matched placebo-treated groups (3.0%). The average duration of treatment with encainide or flecainide in this study was 10 months. The applicability of the CAST results to other populations (e.g., those without recent myocardial infarction) is uncertain. Considering the known proarrhythmic properties of Norpace or Norpace CR and the lack of evidence of improved survival for any antiarrhythmic...

What it is approved for

From the label in effect Aug 24, 2026.

INDICATIONS AND USAGE Norpace and Norpace CR are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. Because of the proarrhythmic effects of Norpace and Norpace CR, their use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of Norpace or Norpace CR treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Norpace CR should not be used initially if rapid establishment of disopyramide plasma levels is desired. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias.

Mechanism: Mechanisms of Action Norpace (disopyramide phosphate) is a Type 1 antiarrhythmic drug (i.e., similar to procainamide and quinidine). In animal studies Norpace decreases the rate of diastolic depolarization (phase 4) in cells with augmented automaticity, decreases the upstroke velocity (phase 0) and increases the action potential duration of normal cardiac cells, decreases the disparity in refractoriness between infarcted and adjacent normally perfused myocardium, and has no effect on alpha- or beta-adrenergic receptors.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 3, 1991 Supplement 48 · Efficacy
  • Jul 19, 1979 Supplement 3 · Efficacy
  • Sep 1, 1977 Original approval · Type 1 - New Molecular Entity · priority review
2 products under this application
  • NORPACE · DISOPYRAMIDE PHOSPHATE EQ 100MG BASE · CAPSULE, ORAL · Prescription · TE AB
  • NORPACE · DISOPYRAMIDE PHOSPHATE EQ 150MG BASE · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Disopyramide" as an intervention, any sponsor and status, largest first.

All 5 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective140
  • off label use59
  • atrial fibrillation48
  • dyspnoea44
  • malaise43
  • fatigue42
  • palpitations32
  • dizziness31
  • asthenia27
  • feeling abnormal27
  • drug interaction23
  • product use issue23

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200421
200536
200613
200721
200813
200913
201042
201151
201253
201326
201471
2015144
201631
201746
201818
201927
202044
202135
202249
202321
202419
202540
202619

Recalls

2 FDA enforcement reports for this application.

  • Dec 2, 2015 · Class III · Terminated

    Failed Dissolution Specification

  • May 31, 2013 · Class III · Terminated

    Failed Dissolution Specification

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Norpace (Disopyramide Phosphate)

2024 spending

$9K

Beneficiaries

n/a

22 claims

Per beneficiary

n/a

$4.49 per unit

View as table
YearSpending
2020$113,012
2021$117,310
2022$24,162
2023$32,331
2024$9,021

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 221 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.